Zealand Pharmaceuticals A/S is set to join what is still an all too select club of European biotechnology firms with a product approval under their belts.
Without much fanfare, Bone Therapeutics SA has begun a pivotal double-blinded Phase III trial of a cell therapy for osteonecrosis, a debilitating bone disorder affecting young adults.
Vaccibody AS received €2 million (US$2.5 million) to have a crack at a problem that has eluded firms with far greater resources: developing an effective therapeutic vaccine against human papillomavirus (HPV) infection.
Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said last week the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief.
Shares in Clavis Pharma ASA (OSLO:CLAVIS) plummeted by more than 87 percent Monday following the failure of CO-101 (CP-4126) to demonstrate any impact on survival in a pivotal Phase II trial in metastatic pancreatic cancer.
Shares in Clavis Pharma ASA (OSLO:CLAVIS) plummeted by more than 87 percent Monday following the failure of CO-101 (CP-4126) to demonstrate any impact on survival in a pivotal Phase II trial in metastatic pancreatic cancer.
Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief.
Poxel SA's lead oral diabetes drug, imeglimin, reached the primary endpoint in a Phase II trial in Type II diabetes patients, demonstrating statistically significant decreases in plasma glucose and fasting plasma glucose levels when administered in combination with sitagliptin vs. treatment with sitagliptin alone.
French diagnostics firm Skuldtech SAS has emerged as the company behind a phenotypic biomarker that offers a simple predictive indication of which pancreatic cancer patients will benefit from an investigational tyrosine kinase inhibitor (TKI) currently under regulatory review in Europe.
